Migraine pathogenesis: Neural and vascular mechanisms

Neurology

Volumn 60, Issue 7 SUPPL. 2, 2003, Pages

  Welch, K Michael ^a   Cutrer, F Michael ^b   Goadsby, Peter J ^c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN CIRCULATION; BRAIN CORTEX; BRAIN STEM; CAUDATE NUCLEUS; CONFERENCE PAPER; HUMAN; MIGRAINE; NERVE CELL EXCITABILITY; NEUROPATHOLOGY; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SPINAL CORD DORSAL HORN; THALAMUS; TRIGEMINAL NERVE;

EID: 0037426426     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology 1994;44:S17-S23.
2. Leao AA. Pial circulation and spreading depression of activity in the cerebral cortex. J Neurophysiol 1944;7:391-463.
3. Leao AA. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944;7:359-390.
4. Lauritzen M, Jorgensen MB, Diemer NH, Gjedde A, Hansen AJ. Persistent oligemia of rat cerebral cortex in the wake of spreading depression. Ann Neurol 1982;12:469-474.
5. 2 response. J Cereb Blood Flow Metab 1984;4:546-554.
6. O'Brien MD. Cerebral-cortex-perfusion rates in migraine. Lancet 1967;1:1036.
7. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of regional cerebral blood flow in classic migraine. Ann Neurol 1981;9:344-352.
8. Cao Y, Welch KM, Aurora S, Vikingstad EM. Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch Neurol 1999;56:548-554.
9. Cutrer FM, Sorensen AG, Weisskoff RM, et al. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol 1998;43:25-31.
10. Woods RP, Iacoboni M, Mazziotta JC. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994;331:1689-1692.
11. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-Fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 1993;13:1167-1177.
12. Feindel W, Penfield W, McNaughton F. The tentorial nerves and localization of intracranial pain in man. Neurology 1960;10:555-563.
13. Edvinsson L, Goadsby PJ. Neuropeptides in headache. Eur J Neurol 1998;5:329-341.
14. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-Fos immunocytochemical study. J Anat 1997;190(part 3):367-375.
15. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993;109:788-792.
16. Liu-Chen LY, Mayberg MR, Moskowitz MA. Immunohistochemical evidence for a substance P-containing trigeminovascular pathway to pial arteries in cats. Brain Res 1983;268:162-166.
17. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999;19:115-127.
18. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-196.
19. Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995;15:384-390.
20. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-187.
21. Lassen LH, Jacobsen VB, Pedersen PA, Sperling B, Iversen HK, Olesen J. Human calcitonin gene-related peptide (hCGRP)-induced headache in migraineurs. Eur J Neurol 1998;5:S63.
22. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56.
23. Drummond PD, Lance JW. Extracranial vascular changes and the source of pain in migraine headache. Ann Neurol 1983;13:32-37.
24. Nichols F III, Mawad M, Mohr JP, Hilal S, Adams RJ. Focal headache during balloon inflation in the vertebral and basilar arteries. Headache 1993;33:87-89.
25. Martins IP, Baeta E, Paiva T, Campos J, Gomes L. Headaches during intracranial endovascular procedures: a possible model of vascular headache. Headache 1993;33:227-233.
26. May A, Ashburner J, Buchel C, et al. Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat Med 1999;5:836-838.
27. Moskowitz MA. Basic mechanisms in vascular headache. Neurol Clin 1990;8:801-815.
28. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 1991;44:97-112.
29. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992;48:187-203.
30. Goadsby PJ, Hoskin KL. Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in cat. Pain 1999;82:15-22.
31. Roon K, Diener HC, Ellis P. CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical trials. Cephalalgia 1997;17:245. Abstract.
32. 1B/1D receptor agonists in migraine: comparative pharmacology and its therapeutic implications. CNS Drugs 1998;10:271-286.
33. Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ. Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res 1993;629:95-102.
34. Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 1991;114(part 2):1001-1011.
35. Goadsby PJ. Pathophysiology of headache. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolffs headache and other head pain, 7th ed. New York: Oxford University Press, 2001:57-72.
36. Hoskin KL, Zagami AS, Goadsby PJ. Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat 1999;194:579-588.
37. Strassman AM, Vos BP, Mineta Y, Naderi S, Borsook D, Burstein R. Fos-like immunoreactivity in the superficial medullary dorsal horn induced by noxious and innocuous thermal stimulation of facial skin in the rat. J Neurophysiol 1993;70:1811-1821.
38. Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-Fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992;106:409-415.
39. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain 1996;119(part 1):249-256.
40. 1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia 1998;18:659-663.
41. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 1997;328:37-40.
42. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain 1996;67:355-359.
43. Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Annu Rev Med 1993;44:145-154.
44. Zagami AS, Lambert GA. Stimulation of cranial vessels excites nociceptive neurones in several thalamic nuclei of the cat. Exp Brain Res 1990;81:552-566.
45. Zagami AS, Lambert GA. Craniovascular application of capsaicin activates nociceptive thalamic neurones in the cat. Neurosci Lett 1991;121:187-190.
46. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1:658-660.
47. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache 1987;27:416-420.
48. Welch KMA, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001;41:629-637.
49. Knight YE, Edvinsson L, Goadsby PJ. Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288. Neuropeptides 1999;33:41-46.
50. Goadsby PJ, Lambert GA, Lance JW. Differential effects on the internal and external carotid circulation of the monkey evoked by locus ceruleus stimulation. Brain Res 1982;249:247-254.
51. Goadsby PJ, Duckworth JW. Low frequency stimulation of the locus ceruleus reduces regional cerebral blood flow in the spinalized cat. Brain Res 1989;476:71-77.
52. Silberstein S, Lipton RB, Goadsby PJ. The pathophysiology of primary headache. In: Silberstein S, Lipton RB, Goadsby PJ, eds. Headache in clinical practice. Oxford: Isis Medical Media, 1998:41-58.
53. Welch KMA, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin 1990;8:817-828.
54. Aurora SK, Ahmad BK, Welch KM, Bhardhwaj P, Ramadan NM. Transcranial magnetic stimulation confirms hyperexcitability of occipital cortex in migraine. Neurology 1998;50:1111-1114.
55. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998;79:964-982.
56. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-624.
57. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543-552.
58. Nyholt DR, Lea RA, Goadsby PJ, Brimage PJ, Griffiths LR. Familial typical migraine: linkage to chromosome 19p13 and evidence for genetic heterogeneity. Neurology 1998;50:1428-1432.
59. Welch KMA, Ramadan NM. Mitochondria, magnesium and migraine. J Neurol Sci 1995;134:9-14.